RU2016109410A3 - - Google Patents

Download PDF

Info

Publication number
RU2016109410A3
RU2016109410A3 RU2016109410A RU2016109410A RU2016109410A3 RU 2016109410 A3 RU2016109410 A3 RU 2016109410A3 RU 2016109410 A RU2016109410 A RU 2016109410A RU 2016109410 A RU2016109410 A RU 2016109410A RU 2016109410 A3 RU2016109410 A3 RU 2016109410A3
Authority
RU
Russia
Application number
RU2016109410A
Other languages
Russian (ru)
Other versions
RU2678315C2 (ru
RU2016109410A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016109410A publication Critical patent/RU2016109410A/ru
Publication of RU2016109410A3 publication Critical patent/RU2016109410A3/ru
Application granted granted Critical
Publication of RU2678315C2 publication Critical patent/RU2678315C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Birds (AREA)
RU2016109410A 2013-09-18 2014-09-17 Аналоги кортистатина для лечения воспалительных и/или иммунопатологических заболеваний RU2678315C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382361.7 2013-09-18
EP13382361 2013-09-18
PCT/EP2014/069842 WO2015040089A1 (en) 2013-09-18 2014-09-17 Co rti statin analogues for the treatment of inflammatory and/or immune diseases

Publications (3)

Publication Number Publication Date
RU2016109410A RU2016109410A (ru) 2017-10-18
RU2016109410A3 true RU2016109410A3 (enExample) 2018-05-24
RU2678315C2 RU2678315C2 (ru) 2019-01-28

Family

ID=49880656

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016109410A RU2678315C2 (ru) 2013-09-18 2014-09-17 Аналоги кортистатина для лечения воспалительных и/или иммунопатологических заболеваний

Country Status (23)

Country Link
US (1) US12297294B2 (enExample)
EP (1) EP3046933B1 (enExample)
JP (1) JP6989260B2 (enExample)
KR (1) KR102285939B1 (enExample)
CN (1) CN105579467B (enExample)
AU (1) AU2014323131B2 (enExample)
BR (1) BR112016005731B1 (enExample)
CA (1) CA2921324C (enExample)
CL (1) CL2016000392A1 (enExample)
DK (1) DK3046933T3 (enExample)
ES (1) ES2728319T3 (enExample)
HU (1) HUE043206T2 (enExample)
IL (1) IL244317B (enExample)
LT (1) LT3046933T (enExample)
MX (1) MX368373B (enExample)
MY (1) MY185593A (enExample)
NZ (1) NZ717035A (enExample)
PL (1) PL3046933T3 (enExample)
PT (1) PT3046933T (enExample)
RU (1) RU2678315C2 (enExample)
SG (1) SG11201601036UA (enExample)
UA (1) UA119148C2 (enExample)
WO (1) WO2015040089A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015100420A1 (en) 2013-12-24 2015-07-02 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) * 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
JP2020526515A (ja) 2017-07-05 2020-08-31 ウィスコンシン・アルムナイ・リサーチ・ファウンデーションWisconsin Alumni Research Foundation 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
JP7324210B2 (ja) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド トファシチニブを含む局所製剤
EP3774848B1 (en) 2018-03-29 2023-02-22 Lateral Ip Pty Ltd Cyclic peptides and uses thereof
RU2698451C1 (ru) * 2018-07-02 2019-08-27 Павел Александрович Храмов Средство и способ для лечения нейросенсорной тугоухости
ES2780274A1 (es) * 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
AU2020397424B2 (en) * 2019-12-05 2025-12-04 Bcn Peptides, S.A. Peptides for the treatment of cancer and/or metastasis
CN111297876B (zh) * 2020-01-16 2021-04-27 武汉理工大学 一种塞来昔布胶束和和厚朴酚胶束药物联用控释系统及其制备方法
CN115120702A (zh) * 2020-03-30 2022-09-30 山东大学齐鲁医院 皮质抑素14在制备银屑病治疗药物中的应用
CN113797314B (zh) * 2021-09-29 2023-08-22 山东大学齐鲁医院 Cst多肽在制备股骨头坏死治疗药物中的应用
CN114949174B (zh) * 2022-07-19 2025-09-30 山东大学齐鲁医院 Cst-14在制备糖尿病皮肤溃疡、破损治疗药物中的应用
CN117866953B (zh) * 2023-03-02 2025-03-07 江西省人民医院 靶向生长激素释放抑制激素基因的shRNA及其医药应用
CN117567554B (zh) * 2023-11-16 2025-03-07 中国科学技术大学 一种荷载抗炎药的凝胶因子、水凝胶及制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2257108A1 (en) * 1996-06-07 1997-12-11 Takeda Chemical Industries, Ltd. Novel peptides and production and use thereof
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1040837A3 (en) 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
WO2007081792A2 (en) 2006-01-05 2007-07-19 University Of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
WO2007082980A1 (es) 2006-01-23 2007-07-26 Consejo Superior De Investigaciones Científicas Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina
WO2009043523A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Cortistatin 17 and neuropeptide 1 for use as therapeutic agent
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
ES2351569B8 (es) * 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.

Also Published As

Publication number Publication date
JP2016535760A (ja) 2016-11-17
CL2016000392A1 (es) 2016-11-11
NZ717035A (en) 2019-11-29
PT3046933T (pt) 2019-05-31
HK1218122A1 (zh) 2017-02-03
AU2014323131B2 (en) 2018-08-09
RU2678315C2 (ru) 2019-01-28
WO2015040089A1 (en) 2015-03-26
MY185593A (en) 2021-05-24
CN105579467B (zh) 2021-03-09
US20160185822A1 (en) 2016-06-30
BR112016005731B1 (pt) 2023-01-17
EP3046933B1 (en) 2019-02-27
HUE043206T2 (hu) 2019-08-28
EP3046933A1 (en) 2016-07-27
IL244317A0 (en) 2016-04-21
KR20160054512A (ko) 2016-05-16
SG11201601036UA (en) 2016-04-28
CA2921324C (en) 2022-11-22
DK3046933T3 (da) 2019-05-13
CN105579467A (zh) 2016-05-11
UA119148C2 (uk) 2019-05-10
JP6989260B2 (ja) 2022-01-05
IL244317B (en) 2020-06-30
MX368373B (es) 2019-09-27
CA2921324A1 (en) 2015-03-26
RU2016109410A (ru) 2017-10-18
MX2016003490A (es) 2016-07-06
BR112016005731A2 (enExample) 2017-08-01
PL3046933T3 (pl) 2019-08-30
KR102285939B1 (ko) 2021-08-05
US12297294B2 (en) 2025-05-13
AU2014323131A1 (en) 2016-03-10
LT3046933T (lt) 2019-05-27
ES2728319T3 (es) 2019-10-23

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112016011851A2 (enExample)
BR112014018502A2 (enExample)
BR112014017739A2 (enExample)
BR112014018480A2 (enExample)
BR112014018516A2 (enExample)
BR112016013956A2 (enExample)
BR112014017855A2 (enExample)
BR112014017765A2 (enExample)
BR112015027947A2 (enExample)
BR112014018468A2 (enExample)
BR112014017901A2 (enExample)
RU2016109410A3 (enExample)
BR112014018207A2 (enExample)
BR112016013859A2 (enExample)
BR112015015948A2 (enExample)
BR112014018578A2 (enExample)
BR112014018483A2 (enExample)
BR112014017794A2 (enExample)
BR112016008877A2 (enExample)
BR112015015312A2 (enExample)
BR112014018353A2 (enExample)
BR112016015170A2 (enExample)
BR112014018496A2 (enExample)
BR112014017745A2 (enExample)